Presentation at J.P. Morgan Healthcare Conference
Telix is pleased to provide a webcast recording of CEO and MD Dr. Christian Behrenbruch presenting at the J.P. Morgan Healthcare Conference on Wednesday 11 January...
Read moreLatest News
Category: News
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has...
Read more
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation...
Read more
Telix Announces Executive Leadership Appointments
Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession...
Read more
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
News,
Telix today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an...
Read more
First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy
Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent...
Read more
Presentation to Jefferies London Healthcare Conference
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November...
Read more
Telix Acquires Optimal Tracers
Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development...
Read more
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...
Read more
EANM 2022 wrap-up : Shifting perspectives in genitourinary oncology through nuclear medicine
At our recent EANM 2022 symposium, Telix brought together some of the world’s key opinion leaders to discuss the impact that nuclear medicine is having on their field. It was...
Read more